iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 prescription trends through June Obesity Interest Sparks Dealmaking Activity
Description
semaglutide (initially 0.24 mg, then 0.5, 1.0, 1.7, finally 2.4 mg) or placebo (51, 52)
It is provided solely for laboratory research purposes and must not be used for diagnostic or therapeutic purposes, in food, cosmetics, or any medical applications
Do not double the dose to make up for a missed one
Our guide to the Wegovy pill covers how it works in more detail
